- Wednesday, 19 March 2014
- AstraZeneca launches NEXIUM® (esomeprazole magnesium) direct-to-patient program AstraZeneca today launched NEXIUM Direct, a program that provides eligible patients the option of having brand-name NEXIUM delivered directly to their home. NEXIUM Direct is part of AstraZeneca Direct, a web-based offering that delivers select brand name prescription medications from AstraZeneca directly to a person’s home.
- Monday, 17 March 2014
- AstraZeneca announces progress on global PARTHENON clinical trial program with BRILINTA (ticagrelor) in high-risk cardiovascular disease patient populations in advance of American College of Cardiology Scientific Session AstraZeneca today announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial EUCLID studying BRILINTA® (ticagrelor) tablets.
- Monday, 3 March 2014
- U.S. FDA approves BYDUREON® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the BYDUREON® Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
- Tuesday, 25 February 2014
- U.S. FDA approves orphan drug MYALEPT™ (metreleptin for injection) AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved MYALEPT™ (metreleptin for injection), which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. MYALEPT, a recombinant analog [laboratory-created form] of human leptin, is the first and only treatment approved by the FDA for these patients.
- Thursday, 20 February 2014
- AstraZeneca patient assistance programs provided more than half a million patients with free medicine in 2013 AstraZeneca announced today that, in 2013, it provided nearly $975 million in savings to more than 567,000 patients in the United States through its patient assistance programs. These programs include AZ&Me and the MedImmune Assistance Program.
- Thursday, 6 February 2014
- AstraZeneca PLC fourth quarter and full year results 2013 Visit our global site to view full details of the event.
- Monday, 3 February 2014
- AstraZeneca completes acquisition of diabetes alliance assets in the U.S. from Bristol-Myers Squibb AstraZeneca today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance.
- Thursday, 16 January 2014
- AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides $5 million grant for American Diabetes Association’s Pathway to Stop Diabetes research initiative AstraZeneca and Bristol-Myers Squibb Company today announced that the companies’ U.S. Diabetes Alliance is providing a three-year grant to the American Diabetes Association’s Pathway to Stop Diabetes program. The innovative research initiative provides resources and support for a new generation of diabetes researchers and is designed to generate exciting discoveries through excellence, innovation, collaboration and radical thinking.
- Monday, 13 January 2014
- U.S. FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FARXIGA should not be used for the treatment of patients with type 1 diabetes or diabetic ketoacidosis.
- Thursday, 12 December 2013
- FDA Advisory Committee recommends the investigational SGLT2 inhibitor dapagliflozin for the treatment of type 2 diabetes in adults AstraZeneca and Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-1 that the benefits of dapagliflozin use outweigh identified risks and support marketing of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The Advisory Committee also voted 10-4 that the data provided sufficient evidence that dapagliflozin, relative to comparators, has an acceptable cardiovascular risk profile.
These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.
View information on AstraZeneca products, including their current US Prescribing Information.